MorphoSys AG, a leader in the field of therapeutic antibodies, announced that its licensee Janssen Inc. (Janssen), previously reported Health Canada approval of Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tremfya (guselkumab) is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya.

Dr. Simon Moroney, chief executive officer of MorphoSys AG, said: "We are very pleased that Tremfya has now been approved in three territories, namely the US, Canada and the European Union. We expect this drug will provide an important treatment option for patients living with moderate-to-severe plaque psoriasis."

Beyond plaque psoriasis, Janssen is studying Tremfya (guselkumab) in a phase 3 psoriatic arthritis development programme.

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.